© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Expert hematologist-oncologists share insight on the E7438-G000-101 clinical trial and consider use of tazemetostat, an EZH2 inhibitor, in relapsed/refractory follicular lymphoma.
September 22nd 2022
Opening their discussion on relapsed/refractory follicular lymphoma (R/R FL), expert participants review the spectrum of available treatments in this setting.
September 29th 2022
Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.